Structuring Collaborative Agreements in Life Sciences
Drafting Terms to Expand Product Lines, Reduce Costs and Risks, and Leverage and Protect Assets
Recording of a 90-minute CLE webinar with Q&A
This CLE webinar will provide guidance to counsel for companies in the life sciences industry for structuring collaborative agreements. The panel will discuss key considerations including allocation of risk, establishment of milestones and obligations, protection of IP rights, and termination of agreements.
- Key considerations
- Contract terms
- Risk allocation
- Roles of parties
- Establishing milestones
- Party obligations
- Development and marketing
- IP rights
- Best practices
The panel will review these and other key issues:
- What considerations and potential pitfalls should counsel keep in mind when crafting collaborative agreements?
- What are the key contract terms that should be included in life sciences collaborative agreements?
- What approaches are most effective for assigning ownership and development rights?
Judith A. Hasko
Latham & Watkins
Ms. Hasko focuses on representing companies developing biotechnology, pharmaceutical, medical device and diagnostic... | Read More
Ms. Hasko focuses on representing companies developing biotechnology, pharmaceutical, medical device and diagnostic products, and investors in such companies, in technology-based commercial transactions. She advises clients in connection with corporate partnering, joint venture, asset purchase, spin-out, licensing, distribution, manufacturing, co-development, profit-sharing and co-promotion matters.Close
Amy L. Toro
Covington & Burling
Ms. Toro specializes in technology transactions, with particular emphasis on life science arrangements, such as... | Read More
Ms. Toro specializes in technology transactions, with particular emphasis on life science arrangements, such as collaboration and license agreements. Her clients include pharmaceutical companies, biotechnology clients, and non-profit organizations. She also has experience with advising high technology clients on matters relating to the development and licensing of standardized technologies.Close